Online inquiry

IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12971MR)

This product GTTS-WQ12971MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12971MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8248MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ785MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ1897MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ4013MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ8330MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ797MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ7800MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GS-HIV
GTTS-WQ3058MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW